Table 1.
Diagnoses of congenital heart disease.
Table 2.
Baseline characteristics of all patients and by MELD-XI score status.
Fig 1.
Comparison of event rate between the high and the low MELD-XI score groups.
During the mean follow-up of 8.6±5.3 years, MACE was noted in 51 patients. The incidence rate of MACE, cardiac death, and HF hospitalization was significantly higher in the high score group compared with the low score group. In contrast, the incidence rate of lethal ventricular arrhythmias was comparable between the two groups. HF, heart failure; MACE, major adverse cardiac events; MELD-XI, model for end-stage liver disease excluding international normalized ratio; p-y, person-year.
Fig 2.
Kaplan-Meier curves according to the MELD-XI score.
The high score group had significantly poor MACE-free survival compared with the low score group (log-rank, P<0.001). MACE, major adverse cardiac events; MELD-XI, model for end-stage liver disease excluding international normalized ratio.
Fig 3.
Kaplan-Meier curves for a subgroup of patients with Fontan circulation.
MACE-free survival was not significantly different between the high and the low score groups (log-rank, P = 0.071). MACE, major adverse cardiac events; MELD-XI, model for end-stage liver disease excluding international normalized ratio.
Fig 4.
Survival CART analysis and prognostic value of the MELD-XI score in ACHD patients.
The survival CART analysis revealed that MELD-XI score was the primary discriminator of MACE (P<0.001), indicating that the score is the most useful prognostic factor for MACE in ACHD patients. ACHD, adult congenital heart disease; AST, aspartate aminotransferase; CART, classification and regression tree; MACE, major adverse cardiac events; MELD-XI, model for end-stage liver disease excluding international normalized ratio; p-y, person-year; SVEF, systemic ventricular ejection fraction.
Table 3.
Univariable Cox regression analysis for prediction of MACE.
Table 4.
Multivariable Cox regression analysis for prediction of MACE.